Cat. #153397
Anti-MUC1 [C789]
Cat. #: 153397
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: MUC1
Class: Monoclonal
Application: IHC
Reactivity: Human ; Xenopus laevis
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Mike Price
Institute: University of Nottingham
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-MUC1 [C789]
- Alternate name: CD227; KL6; Mucin 1; PEMT
- Cancer: Breast cancer;Gynaecologic cancer
- Cancers detailed: Breast cancer;Broadly Applicable;Colon;Ovarian
- Research fields: Cancer;Cell biology;Genetics
- Clone: C789
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Molecular weight: 122 kDa
- Reactivity: Human ; Xenopus laevis
- Host: Mouse
- Application: IHC
- Description: MUC1/CA 15-3 is used as a serological clinical marker of breast cancer to monitor response to breast cancer treatment and disease recurrence. Decreased levels over time may be indicative of a positive response to treatment. Conversely, increased levels may indicate disease progression. At an early stage disease, only 21% of patients exhibit high MUC1/CA 15-3 levels, that is why CA 15-3 is not a useful screening test. Most antibodies target the highly immunodominant core peptide domain of 20 amino acid (APDTRPAPGSTAPPAHGVTS) tandem repeats. Some antibodies recognize glycosylated epitopes. Medullary cystic kidney disease 1.
- Immunogen: need access to this paper to answer this - https://www.ncbi.nlm.nih.gov/pubmed/?term=fine+specificity+of+antibody+recognition+of+carcinoma-associated+epithelial+musincs
Target Details
- Target: MUC1
- Molecular weight: 122 kDa
- Target background: MUC1/CA 15-3 is used as a serological clinical marker of breast cancer to monitor response to breast cancer treatment and disease recurrence. Decreased levels over time may be indicative of a positive response to treatment. Conversely, increased levels may indicate disease progression. At an early stage disease, only 21% of patients exhibit high MUC1/CA 15-3 levels, that is why CA 15-3 is not a useful screening test. Most antibodies target the highly immunodominant core peptide domain of 20 amino acid (APDTRPAPGSTAPPAHGVTS) tandem repeats. Some antibodies recognize glycosylated epitopes. Medullary cystic kidney disease 1.
Applications
- Application: IHC
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -80° C
- Shipping conditions: Dry ice
References
- Croce et al. 1997. Anticancer Res. 17(6D):4287-92. PMID: 9494522.
- Expression of tumour associated antigens in normal, benign and malignant human mammary epithelial tissue: a comparative immunohistochemical study.
